DEPDC1B: A novel tumor suppressor gene associated with immune infiltration in colon adenocarcinoma

Abstract

AbstractBackgroundRecent research indicates a positive correlation between DEP structural domain‐containing 1B (DEPDC1B) and the cell cycle in various tumors. However, the role of DEPDC1B in the infiltration of the tumor immune microenvironment (TIME) remains unexplored.MethodsWe analyzed the differential expression and prognostic significance of DEPDC1B in colon adenocarcinoma (COAD) using the R package “limma” and the Gene Expression Profiling Interactive Analysis (GEPIA) website. Gene set enrichment analysis (GSEA) was employed to investigate the functions and interactions of DEPDC1B expression in COAD. Cell Counting Kit‐8 (CCK‐8) assays and colony formation assays were utilized to assess the proliferative function of DEPDC1B. Correlations between DEPDC1B expression and tumor‐infiltrating immune cells, immune checkpoints, tumor mutational burden (TMB), and microsatellite instability (MSI) status were examined using Spearman correlation analysis and CIBERSORT.ResultsDEPDC1B was highly expressed in COAD. Elevated DEPDC1B expression was associated with lower epithelial‐to‐mesenchymal transition (EMT) and TNM stages, leading to a favorable prognosis. DEPDC1B mRNA was prominently expressed in COAD cell lines. CCK‐8 and colony formation assays demonstrated that DEPDC1B inhibited the proliferation of COAD cells. Analysis using the CIBERSORT database and Spearman correlation revealed that DEPDC1B correlated with four types of tumor‐infiltrating immune cells. Furthermore, high DEPDC1B expression was linked to the expression of PD‐L1, CTLA4, SIGLEC15, PD‐L2, TMB, and MSI‐H. High DEPDC1B expression also indicated responsiveness to anti‐PD‐L1 immunotherapy.ConclusionsDEPDC1B inhibits the proliferation of COAD cells and positively regulates the cell cycle, showing a positive correlation with CCNB1 and PBK expression. DEPDC1B expression in COAD is associated with tumor‐infiltrating immune cells, immune checkpoints, TMB, and MSI‐H in the tumor immune microenvironment. This suggests that DEPDC1B may serve as a novel prognostic marker and a potential target for immunotherapy in COAD.